Study of FCN-011 in Patients With Advanced Solid Tumor（Phase I）and NTRK Fusion Positive Advanced Solid Tumor （Phase II）
Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
A multicenter, open, single-arm phase I dose exploration and phase II extended study was
conducted to evaluate the safety, tolerability, pharmacokinetic characteristics, and primary
antitumor activity of FCN-011 in patients with advanced solid tumor (phase I) and NTRK fusion
positive advanced solid tumor (phase II)